Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Significant Drop in Short Interest

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 21,100 shares, a decrease of 60.9% from the February 28th total of 53,900 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 28,500 shares, the days-to-cover ratio is currently 0.7 days.

Inhibitor Therapeutics Stock Down 3.3 %

Inhibitor Therapeutics stock traded down $0.00 during mid-day trading on Friday, hitting $0.06. 2,000 shares of the company’s stock were exchanged, compared to its average volume of 39,043. The company’s 50 day simple moving average is $0.06 and its 200-day simple moving average is $0.07. The firm has a market capitalization of $9.99 million, a P/E ratio of -5.80 and a beta of -0.55. Inhibitor Therapeutics has a fifty-two week low of $0.04 and a fifty-two week high of $0.14.

Inhibitor Therapeutics (OTCMKTS:INTI) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.01) earnings per share for the quarter.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.